drug_type
RELEVANT_DRUG
intervention_type
Biologic immunotherapy (monoclonal antibody)
drug_description
Murine IgG1 monoclonal antibody against CA125 (MUC16); forms immune complexes with tumor-associated and circulating CA125 to enhance dendritic cell antigen uptake and elicit CA125-specific T- and B-cell responses; can mediate Fc-dependent effector functions (ADCC/complement).
nci_thesaurus_concept_id
C1784
nci_thesaurus_preferred_term
Oregovomab
nci_thesaurus_definition
A murine monoclonal antibody that attaches to the tumor-associated antigen CA125. Vaccination with monoclonal antibody B43.13 may stimulate a host cytotoxic immune response against tumor cells that express CA125. (NCI04)
drug_mesh_term
Oregovomab
drug_category
IMMUNOGENIC PROTEIN
drug_class
Vaccine
drug_delivery_route
Intravenous
drug_mechanism_of_action
Murine IgG1 monoclonal antibody against CA125 (MUC16) that binds tumor-associated and circulating CA125 to form immune complexes, enhancing dendritic cell uptake and presentation to elicit CA125-specific T- and B-cell responses; can also trigger Fc-mediated effector functions (ADCC and complement).
drug_name
Oregovomab
nct_id_drug_ref
NCT05605535